Lauren E. Sedita, MS
Articles
January 14th 2025
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
Jason Shafrin, PhD Suhail Thahir, MS Alexa C. Klimchak, MA Ivana Audhya, MSc Lauren E. Sedita, MS John A. Romley, PhD
Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
July 10th 2024
Quantifying the Insurance Value for Rare Diseases: Duchenne Muscular Dystrophy
Jason Shafrin, PhD Suhail Thahir, MS Alexa C. Klimchak, MA Ivana Audhya, MSc Lauren E. Sedita, MS John A. Romley, PhD
The degree to which novel value elements such as insurance value impact estimated treatment value for rare, severe genetic diseases such as Duchenne muscular dystrophy is unclear.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: December 14th 2024 | Updated: January 22nd 2025
MagnetisMM-20: Priming Myeloma Tumor Cells for the Bispecific Bout
